We strive to treat more patients with ground-breaking therapies. This mission inspires and motivates us.
Strategy for value creation
Actelion’s strategy is designed to create value by leveraging the Company’s many strengths. These include its global leadership in the field of pulmonary arterial hypertension (PAH) therapy, a strong and effective specialty commercial organization, and a unique company culture that focuses on delivering innovative medicines that improve patient’s lives.
We are the leaders in PAH therapy and, with our PAH products, we will continue to lead well into the future. During this time we must advance our pipeline products in new therapeutic areas to find additional meaningfully differentiated products to benefit patients.
As a new member of the Johnson & Johnson Family of Companies, we are working closely to leverage Johnson & Johnson’s global presence and commercial strength to accelerate growth and patient access to our important therapies.